Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Short Interest Up 189.0% in January

Estrella Immunopharma, Inc. (NASDAQ:ESLAW) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 17,060 shares, a growth of 189.0% from the December 31st total of 5,904 shares. Based on an average daily trading volume, of 3,229 shares, the days-to-cover ratio is currently 5.3 days. Based on an average daily trading volume, of 3,229 shares, the days-to-cover ratio is currently 5.3 days.

Estrella Immunopharma Stock Performance

Shares of NASDAQ:ESLAW opened at $0.06 on Friday. Estrella Immunopharma has a 52-week low of $0.03 and a 52-week high of $0.24. The stock’s fifty day simple moving average is $0.06 and its 200-day simple moving average is $0.07.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.